NeuroScientific Biopharmaceuticals (ASX:NSB) has announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB.
The company described the recruitment as a significant milestone in the development of EmtinB as a first-in-class treatment with disease-modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer’s disease.
The early-phase clinical trial is being undertaken by WA-based clinical research partner Linear Clinical Research.
NeuroScientific managing director and CEO Matt Liddelow said, “Following the recent important announcement of securing our first HREC approval for a clinical trial, the recruitment of the first subject for the early-phase clinical trial marks another historic achievement for the Company and a major milestone in developing EmtinB as a much needed therapeutic treatment with disease-modifying potential for patients with Multiple sclerosis and Alzheimer’s disease.”
The company said the early-phase clinical trial will include up to 30 healthy volunteers. A focus will be the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB in humans.